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ORIGINAL ARTICLE
COPD
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ABSTRACT Accurate and consistent determination of cause of death is challenging in chronic obstructive
pulmonary disease (COPD) patients. TIOSPIR (N=17 135) compared the safety and efficacy of tiotropium
Respimat 5/2.5 µg with HandiHaler 18 µg in COPD patients. All-cause mortality was a primary end-point. A
mortality adjudication committee (MAC) assessed all deaths. We aimed to investigate causes of discordance
in investigator-reported and MAC-adjudicated causes of death and their impact on results, especially cardiac
and sudden death.
The MAC provided independent, blinded assessment of investigator-reported deaths (n=1302) and assigned
underlying cause of death. Discordance between causes of death was assessed descriptively (shift tables).
There was agreement between investigator-reported and MAC-adjudicated deaths in 69.4% of cases at
the system organ class level. Differences were mainly observed for cardiac deaths (16.4% investigator, 5.1%
MAC) and deaths assigned to general disorders including sudden death (17.4% investigator, 24.6% MAC).
Reasons for discrepancies included investigator attribution to the immediate (e.g. myocardial infarction
(MI)) over the underlying cause of death (e.g. COPD) and insufficient information for a definitive cause.
Cause-specific mortality varies in COPD, depending on the method of assignment. Sudden death,
witnessed and unwitnessed, is common in COPD and often attributed to MI without supporting evidence.
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Introduction
Accurate determination of cause of death is challenging in patients with chronic obstructive pulmonary
disease (COPD) because of the high comorbidities and complex clinical scenarios at the time of death.
Consistent attribution of cause of death is important in all clinical trials, especially when mortality is an
outcome measure and causes of death are of interest. The TIOtropium Safety and Performance In Respimat
(TIOSPIR) trial [1] was conducted to clarify a potential risk for increased death with tiotropium Respimat,
because a higher number of deaths was observed in studies with tiotropium Respimat versus placebo, albeit
on a limited number of deaths [1–3]. However, tiotropium HandiHaler was associated with a lower
probability of death versus placebo in the 4 year Understanding the Potential Long-term Impacts on
Function with Tiotropium (UPLIFT) study as well as in the overall HandiHaler database [4, 5]. As the
imbalance in the Respimat studies appeared to be prominent in patients with arrhythmias at study entry,
cardiovascular deaths, including sudden (cardiac) deaths, were of special interest for two main reasons.
First, sudden deaths are not always caused by cardiac disease [6], despite often being mislabelled as such
and despite evidence that patients with COPD are at increased risk of sudden cardiac death. Second,
sudden death presents unique difficulties because it commonly occurs outside the hospital and is frequently
unwitnessed [7, 8].
Similar to the UPLIFT trial [4, 9], a mortality adjudication committee (MAC) was established in TIOSPIR
to provide a systematic, independent, blinded assessment of cause-specific mortality reported by the
investigators. We therefore undertook a post hoc analysis of the data on mortality and attributed causes of
death in the TIOSPIR trial.
Here, we describe the process of mortality adjudication in the TIOSPIR trial and compare
investigator-reported versus adjudicated results for system organ class (SOC) and specific causes of death
of interest, with a specific focus on cardiovascular death, including sudden death. In particular, we aimed
to evaluate the impact of a standardised adjudication process on the assessment of cause-specific mortality.

Materials and methods
TIOSPIR study design
The TIOSPIR study was a randomised, double-blind, parallel-group trial (17 135 patients with COPD)
comparing the safety and efficacy of tiotropium Respimat 2.5 or 5 μg versus tiotropium HandiHaler 18 μg.
The primary safety end-point was time to all-cause mortality. Other outcome measures included time to
first major adverse cardiovascular event (MACE), which comprised stroke, myocardial infarction (MI),
sudden death, cardiac death, sudden cardiac death and fatal event in the SOCs for cardiac and vascular
disorders [1, 3].
The trial was performed in accordance with the Declaration of Helsinki, and the study protocol and
procedures were approved by relevant institutional review boards and ethics committees, as described
previously [1]. All patients provided written informed consent.
MAC documentation and adjudication processes in the TIOSPIR study
Adverse events were triaged by medical doctors (medical reviewers/event monitors) and reviewed in
priority order for completeness and medical consistency before sending to MAC (supplementary material).
The MAC comprised three pulmonologists (including the chair of the MAC), three cardiologists, an
oncologist and a general medicine member (internist). A set of questions was developed for the medical
reviewers/event monitors as a resource for the investigational sites to maximise information from patients
who initially presented with no or minimal information. The objective of the MAC was to provide
continuous, systematic, independent, blinded, expert assessment of investigator-reported deaths. The MAC
assigned a single primary cause of death coded to preferred term level using the Medical Dictionary for
Regulatory Activities (MedDRA) according to specific rules devised for the TIOSPIR trial within their
principles of operation (supplementary material), which also incorporated many of the general principles
and methods generally used in the classification of primary cause of death. However, the site investigators
were not made aware of the principles of operation utilised by the MAC [10]. A quality control process
evaluated the reliability of the adjudication process (supplementary material).
Based on definitions by the World Health Organization, the American College of Cardiology and the
American Heart Association [11–13], the MAC defined sudden cardiac deaths as those occurring within
1 h of an abrupt change of a person’s clinical state without other obvious non-cardiac cause, while sudden
death referred to deaths occurring more than 1 h but less than 24 h after the patient was last observed
alive and without evidence of a deteriorating medical condition. The site investigators did not have access
to the principles of operation utilised by the MAC.
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Statistical analysis
Concordance and discordance between investigator-reported and MAC-adjudicated causes of death (SOC
and preferred term) were assessed using shift tables. Given that the analysis was not treatment-related, data
from the three treatment arms were pooled.
Additionally, a sensitivity analysis of MACE, including the term “death unknown”, was performed.
Investigator-reported and MAC-adjudicated fatal events of MACE and its individual components were
compared for the tiotropium Respimat 5 µg and HandiHaler 18 µg treatment groups using rate ratios.

Results
Numbers of deaths and autopsies
Vital status at the conclusion of the trial was ascertained in 99.7% of participants. There were 1302 deaths:
440 in the tiotropium Respimat 2.5 μg group, 423 in the Respimat 5 μg group and 439 in the tiotropium
HandiHaler 18 μg group. Although about 382 autopsies were performed, their results were frequently not
available for review and, in many cases, were uninformative.
Causes of death
The classification by SOC of investigator-reported versus MAC-adjudicated cause of death as a percentage
of deaths is summarised in figure 1. The three leading causes of death, at the SOC level, according to both
the investigators and the MAC, were respiratory, neoplasm and general (figure 1, table S1). However, there
were notable differences in the number of deaths attributed to each of the SOC categories by the MAC
compared with the investigators (figure 1, table S1). Differences were especially marked for the cardiac
deaths SOC, where the number of deaths was higher when investigator-reported (n=214; 16.4%) than
when MAC-adjudicated (n=66; 5.1%). On the other hand, deaths due to general disorders and neoplasms
were higher when MAC-adjudicated (n=320; 24.6% and n=305; 23.4%, respectively) than when
investigator-reported (n=226; 17.4% and 249; 19.1%, respectively). The number of deaths due to
respiratory causes was also higher when MAC-adjudicated (n=369; 28.3%) than when investigator-reported
(n=326; 25.0%) (table S1). There was agreement (concordance), at the SOC level, of the MAC-adjudicated
cause of death with the investigator-reported cause of death in 904 of 1302 (69.4%) cases. Concordance
was highest for cancer-related deaths (neoplasms) (247 of 249 cases, 99.2%). However, due to the “cancer
rule” (supplementary material), the MAC found 58 additional cancer cases, of which 23 were assigned
MedDRA terms for lung cancer. Concordance was lowest for cardiac deaths: just 58 of the 214 cases
(27.1%). Of the 156 discordant cases, 74 (47.4%) were adjudicated to sudden death or sudden cardiac
death, 36 to respiratory (23.1%), 11 to neoplasm (7.1%), 10 to infections (6.4%) and the remaining 6 cases

Patients with death % by SOC

2.5

Adjudicated deaths
Investigator-reported deaths

2.0

1.5

1.0

0.5

Vascular disorders

Respiratory, thoracic and
mediastinal disorders

Psychiatric disorders

Nervous system disorders

Neoplasms (benign,
malignant and unspeciﬁed)

Injury, poisoning and
procedural complications

Infection and infestations

General disorders (including
sudden (cardiac) death)

Gastrointestinal disorders

Cardiac disorders

0

FIGURE 1 Classification of investigator-reported and MAC-adjudicated causes of death, as a percentage of
patients with death by system organ class (SOC). MAC: mortality adjudication committee.
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to other causes (3.9%), while 19 were identified by the investigator as cardiorespiratory arrest (n=6),
cardiopulmonary failure (n=8) or cor pulmonale (n=5). Moreover, of the 36 cases initially determined as
cardiac by the investigator, but adjudicated to respiratory by the MAC, 33 were assigned COPD as the
specific cause of death by the MAC.
Discordance was high for the SOC category of infections (70 of 148 (47.3%)) and respiratory deaths (63 of
326 cases (19.3%)) (table S1), although discordance in the SOC respiratory was much less than in SOC
cardiac (156 of 214 (72.9%)). Thirty-one (49.2%) of the discordant respiratory cases were assigned to
general, which includes sudden cardiac death (n=9) or sudden death (n=12), by the MAC; another 16
cases to cancer (lung neoplasm malignant, small-cell lung cancer, lung cancer metastatic); and 6 cases to
infection ( pneumonia). On the other hand, the MAC reassigned 36 cardiac deaths, 30 general deaths and
33 infections deaths to respiratory causes, with 96 of these 99 cases assigned to the preferred term COPD.
Detailed assessment of cardiac deaths focused on just the investigator-reported cases of fatal MI (n=46),
comprising the specific diagnoses acute MI/MI, post-procedural MI and acute coronary syndrome (table 1).
The MAC-adjudicated cause of death, comprising seven specific diagnostic terms, was concordant in 21 of
46 cases (45.7%). The two main reasons for the differences in assignment of cause of death between
investigators and adjudicators were that the MAC protocol required that the underlying cause of death be
recorded and that specific documentation be cited in order to assign certain causes of death. In four cases
where there was discordance between an investigator-reported fatal MI and the adjudicated cause of death,
an underlying cause of death (e.g. aortic aneurysm, brain neoplasm or COPD) was provided. In 21 cases,
insufficient documentation was available to assign an underlying cause of death, leading to the assignment
of a more general term (death, sudden death or sudden cardiac death).
Sensitivity analysis
The composite end-points of fatal MACE and fatal MACE plus unknown death showed similar numbers of
investigator-reported and MAC-adjudicated deaths for the tiotropium Respimat 5 µg and HandiHaler 18 µg
treatment groups (figure 2). Incidence rates for the individual components within these composites, including
sudden death and sudden cardiac death, were also similar, with the 95% CI of most of the rate ratios
including 1. However, although numbers were very small, there was a between-treatment difference for
MAC-adjudicated MI deaths: more deaths were attributed to MI in the tiotropium Respimat group than in the
HandiHaler group (n=11 versus 3; rate ratio (95% CI) 3.64 (1.02‒13.06) for tiotropium HandiHaler 18 µg versus
tiotropium Respimat).

Discussion
Reliable reporting of causes of death in clinical trials is essential to ensure the safety of medicines.
However, it can be difficult to accurately determine cause of death in patients with COPD due to the
presence of comorbidities and the tendency of attributing sudden death, especially when unwitnessed, to a
cardiac cause [14]. Studies have concluded that a MAC [9] (or a clinical end-point committee) [14] can
provide reliable, standardised adjudication of COPD mortality, which may differ from investigator-assessed
cause of death. Moreover, the quality control exercise used to assess the reliability of adjudicated
cardiovascular causes of death within the TIOSPIR trial exceeded the target, with a proportion agreement
TABLE 1 Comparison of investigator-reported fatal myocardial infarction (MI)# with adjudicated terms
Causes of death by MAC
Concordance

Discordance
Underlying cause of death

Causes by investigator

Acute MI/MI
Post-procedural MI
Acute coronary syndrome
Total

Lack of information or evidence¶

Acute MI/MI

Aortic
aneurysm

Brain
neoplasm

Chronic obstructive
pulmonary disease

Death

Sudden
cardiac death

Sudden
death

Total

21

1
1

1

1

4

8

6

21

2

1

1

4

1
9

2
8

42
1
3
46

MAC: mortality adjudication committee. #: MI is SMQ (standardised MedDRA query) ischaemic heart disease, sub-SMQ MI. ¶: there was
insufficient information/evidence for the MAC to assign a specific underlying cause of death so the categorical assignment was made based on
MAC protocol-defined criteria. Sudden cardiac deaths were those occurring within 1 h of an abrupt change of a person’s clinical state without
other obvious non-cardiac cause, and sudden death refers to those occurring more than 1 h but less than 24 h of the patient last being
observed alive and without evidence of a deteriorating medical condition. “Death” refers to unexplained death.

https://doi.org/10.1183/23120541.00073-2016

4

COPD | R.A. WISE ET AL.

Deaths n (IR)
adjudicated/investigator
Tiotropium
Respimat 5 µg
n=5711

Tiotropium
HandiHaler 18 µg
n=5694

423 (3.22)

439 (3.36)

113 (0.86)/
121 (0.92)

101 (0.77)/
125 (0.96)

Cardiac disorders (SOC)

27 (0.21)/
73 (0.56)

17 (0.13)/
72 (0.55)

Myocardial infarction#

11 (0.08)/
14 (0.11)

3 (0.02)/
13 (0.10)

Vascular disorders (SOC)

3 (0.02)/
7 (0.05)

5 (0.04)/
12 (0.09)

Stroke (PV)

14 (0.11)/
15 (0.11)

11 (0.08)/
12 (0.09)

Sudden death (PT)

38 (0.29)/
16 (0.12)

46 (0.35)/
19 (0.15)

Cardiac death (PT)

2 (0.02)/
0 (0.00)

0 (0.00)/
2 (0.02)

Sudden cardiac death (PT)

29 (0.22)/
10 (0.08)

22 (0.17)/
7 (0.05)

140 (1.07)/
158 (1.20)

138 (1.06)/
166 (1.27)

27 (0.21)/
37 (0.28)

37 (0.28)/
41 (0.31)

Total deaths
Fatal MACE

Fatal MACE including death unknown
Death unknown (PT)

Adjudicated of death
Investigator-reported causes of death

0.1
Favours Tiotropium
Respimat 5 µg

1
Rate ratio
(95% CI)

10
Favours Tiotropium
HandiHaler 18 µg

FIGURE 2 Comparison of investigator-reported and mortality adjudication committee-adjudicated fatal events (myocardial infarction, sudden death,
sudden cardiac death and death) in the tiotropium Respimat 5 µg and HandiHaler 18 µg treatment groups. IR: incidence rate per 100 patient-years;
MACE: major cardiovascular event; SOC: system organ class; PV: pharmacovigilance term; PT: preferred term; #: standardised MedDRA query (SMQ)
ischaemic heart disease, sub-SMQ myocardial infarction.

of 94% (“almost perfect”), confirming the reliability and reproducibility of the assignment. This level of
reproducibility cannot be expected by investigator assessments, as noted in this study, although
investigators had access to the same level of information as the MAC.
Here, we have shown that discordance between investigator-reported and MAC-adjudicated causes of
death exists, in particular for cardiovascular deaths, with investigators attributing more deaths to cardiac
causes (SOC) than the MAC, and the MAC assigning more to sudden death and sudden cardiac deaths
(both categorised as general disorders SOC by MedDRA). The inclusion of sudden death in general versus
cardiovascular SOC could be a reason for the shift in attribution from cardiovascular to general disorders
SOC in the MAC-adjudicated versus investigator-reported causes of death. The difference between the
number of MAC-adjudicated and investigator-reported cases of cardiac death in the UPLIFT trial was
similar to that reported here for TIOSPIR; in both trials there was a three-fold greater incidence of
investigator-reported cardiac deaths [9].
Moreover, the MAC shifted 58 deaths from other categories to cancer as the underlying cause of death. This is
due to the MAC policy that deaths of all patients with incurable cancers should be attributed to the cancer,
regardless of the terminal event, which may have been related to secondary complications of the cancer or
treatment for the cancer. There was also a shift from general, infectious and cardiovascular causes to
respiratory, largely due to the policy that all patients whose terminal illness was initiated by a COPD
exacerbation should have the death attributed to respiratory, regardless of the terminal event, which may have
been pneumonia, sepsis, MI or sudden death. Thus, although MAC adjudication changed the attribution of
cause of death in the TIOSPIR study in just over 30% of cases, this resulted primarily from attribution of death
to the underlying cause of the terminal illness (e.g. COPD) rather than the immediate cause of death (e.g. MI).
In the Towards a Revolution in COPD Health (TORCH) study, causes of death were adjudicated by a
three-physician clinical end-point committee [14]. Because there were no generally agreed definitions, they
developed their own set of working definitions for categories of death in a COPD clinical trial population.
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Based on this experience, several modifications were recommended for future clinical trials of COPD
mortality, including the suggestion that sudden death should be considered as a separate entity, rather than
one linked necessarily to a cardiovascular cause [14]. Therefore, adjudication in TIOSPIR used the MedDRA
classification. The apparent preferential categorisation of a COPD death as cardiac by investigators in the
TORCH, UPLIFT and TIOSPIR studies may also reflect a general tendency of investigators to report the
mechanism of death (such as MI), rather than the underlying cause of death. Cause of death is often
attributed to MI when the actual cause of death is unknown. This could be reflected in the tendency of
medical examiners to label sudden deaths as MI. In fact, sudden cardiac death is usually overestimated.
Previous studies have confirmed that pre-existing coronary heart disease or congestive heart failure increase
the risk of sudden death [15–17] and account for almost 75% of sudden cardiac deaths in the western world
[18–20]. It is noteworthy that the deaths classified as sudden cardiac are often non-cardiac [21] and a
significant proportion of out-of-hospital cardiac arrests in COPD patients is attributable to underlying lung
disease [22]. Likewise, a study by HUIART et al. and the Rotterdam study emphasised that COPD was
associated with an increased risk of sudden cardiac death [8] and a two- to three-fold higher risk of
cardiovascular disease, thereby contributing to almost 50% of deaths [8, 23]. Although the MAC
distinguished between sudden cardiac death (last seen alive within 1 h), sudden death (last seen alive between
1 and 24 h) and death (last seen alive >24 h ago), these distinctions may depend more on the circumstances
of death than the actual cause of death and therefore are not useful distinctions. Moreover, death that occurs
more than 1 h and less than 24 h from last being seen clinically stable should not routinely be assigned to a
cardiac cause, especially in a study of COPD patients, because of the likelihood that a non-trivial percentage
of these cases will be determined to have had a respiratory cause of death [6, 24].
An analysis of data from death certificates from England and Wales (1993–1999) reported that using the
immediate cause of death underestimates the contribution of obstructive lung disease to mortality [24]. This
was supported by a TORCH death certificate analysis, which found that COPD was often not mentioned [25].
In contrast, in death certificates that mention MI, it was the underlying cause in 94% of cases [26]. Although
this difference did not alter the interpretation of the between-treatment analyses in the UPLIFT trial, such
discrepancies could potentially alter the interpretation of a clinical trial in which there was a smaller difference
between treatment arms. In TIOSPIR, there were more deaths attributed to MI by the MAC in the tiotropium
Respimat arm than in the HandiHaler arm (11 versus 3). This difference arose because there were a larger
number of cases in the tiotropium Respimat arm for which sufficient data were available to actually make the
diagnosis of MI according to the MAC rules (such as electrocardiogram results and cardiac enzyme levels),
whereas this was less often the case in the HandiHaler arm. This between-treatment result was not observed
when all cardiovascular deaths (fatal MACE) were considered, or when proportions of sudden deaths and
sudden cardiac deaths were compared, demonstrating the usefulness of composite MACE end-points. For
periods up to 48 weeks, tiotropium maintenance therapy administered using Respimat or HandiHaler once
daily was not associated with an increased risk of cardiac arrhythmia in patients with COPD [27].
Furthermore, mortality and subsequent cardiac events were not increased versus placebo in the UPLIFT trial in
patients with an acute arrhythmia event [28].
Death may be the end result of a complex series of sequential and contemporaneous factors. Therefore,
attributing a single cause of death is often artificial. However, attributing death to the final illness is both logical
and leads to consistency of adjudication. Unknown cause of death will always remain an issue in some cases,
either because there is a lack of source documentation to assign a definitive cause or because the cause is
genuinely unknown despite adequate documentation. In addition, the multiple comorbidities present in most
COPD patients make the assignment of a single cause of death particularly difficult. These limitations with
respect to assigning a specific cause of death suggest that the results of the MAC adjudication process, while
reliable, may not be accurate if documentation is not available. Moreover, adjudication of the underlying cause
of death may underestimate the relevance of factors contributing to the immediate cause of death. Therefore,
small differences in cause-specific deaths in COPD clinical trials should be interpreted with caution. Although
the approach outlined in this study provides for a consistent and reliable ascertainment of cause of death for
studies of COPD, it should be noted that this approach may not be applicable for all clinical trials.
Furthermore, we suggest that study coordination staff and investigators should be trained to scrutinise the
nature and timing of events preceding an unexpected sudden death for future trials.
The findings from this study confirm the value of using all-cause mortality and composite cardiovascular
end-points in COPD trials, such as MACE, grouping specific causes of death like sudden (cardiac) death,
rather than cause-specific mortality as an outcome in COPD trials, given the difficulty in ascertaining a
reliable cause of death in individual cases.
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